We serve Chemical Name:[4-(6-methylpyrazin-2-yl)oxyphenyl]methanamine CAS:926921-67-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![[4-(6-methylpyrazin-2-yl)oxyphenyl]methanamine](https://a.dearchem.com/CAS2/926921-67-7.png)
Chemical Name:[4-(6-methylpyrazin-2-yl)oxyphenyl]methanamine
CAS.NO:926921-67-7
Synonyms:[4-(6-methylpyrazin-2-yl)oxyphenyl]methanamine
Molecular Formula:C12H13N3O
Molecular Weight:215.25100
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:354.6ºC at 760 mmHg
Density:1.177g/cm3
Index of Refraction:1.595
PSA:61.03000
Exact Mass:215.10600
LogP:2.73630
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like [4-(6-methylpyrazin-2-yl)oxyphenyl]methanamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[4-(6-methylpyrazin-2-yl)oxyphenyl]methanamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[4-(6-methylpyrazin-2-yl)oxyphenyl]methanamine Use and application,[4-(6-methylpyrazin-2-yl)oxyphenyl]methanamine technical grade,usp/ep/jp grade.
Related News: The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD. [4-(6-methylpyrazin-2-yl)oxyphenyl]methanamine manufacturer Also, the study did not compare people who had COVID-19 with those who did not, to see if such symptoms were higher than in the general population. The report did exclude patients with certain serious or chronic preexisting conditions like cancer, kidney disease, HIV, liver disease and stroke, to separate their previous health status from post-COVID symptoms. [4-(6-methylpyrazin-2-yl)oxyphenyl]methanamine supplier Their pharmacological activity plays a direct role in the diagnosis, cure, mitigation, treatment, or prevention of disease. [4-(6-methylpyrazin-2-yl)oxyphenyl]methanamine vendor The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD. [4-(6-methylpyrazin-2-yl)oxyphenyl]methanamine factory Their pharmacological activity plays a direct role in the diagnosis, cure, mitigation, treatment, or prevention of disease.
